Continuous Glucose Monitoring in Diabetes and Prediabetes

NACompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

July 3, 2020

Study Completion Date

July 3, 2020

Conditions
Diabetes Mellitus, Type 2PreDiabetesObesity
Interventions
DEVICE

DEXCOM G6 RT-CGM

CGM is a way to measure glucose levels in real-time. A tiny electrode called a glucose sensor is inserted under the skin to measure glucose levels in tissue fluid. A small plastic piece of tube remains inserted in the skin. It is connected to a transmitter that sits on top of the skin. It is approved for use on the abdomen for 10 days. It either records the sugars downloaded in the clinic (blinded part of the study) or it sends the information via wireless radio frequency to a monitoring/ display device or to a cellular phone so participants can see data. DEXCOM G6 is FDA approved for use in patients with diabetes and will be used in accordance with instructions as approved for diabetes.

Trial Locations (1)

20037

GWU Medical Faculty Associates, Washington D.C.

All Listed Sponsors
collaborator

DexCom, Inc.

INDUSTRY

lead

Nicole Ehrhardt, MD

OTHER

NCT03805412 - Continuous Glucose Monitoring in Diabetes and Prediabetes | Biotech Hunter | Biotech Hunter